MYMODFA
DEAD

Serial Number

90702290

Owner

MyoKardia, Inc.

Attorney

Marilyn F. Kelly

Filing Date

May 11, 2021

Add to watchlist:

No watchlists yet
View on USPTO

MYMODFA Trademark

Serial Number: 90702290

MYMODFA is a trademark filed by MyoKardia, Inc. on May 11, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

MyoKardia, Inc. (38 trademarks)

Brisbane, CA 94005

Entity Type: 03

Trademark Details

Filing Date

May 11, 2021

Registration Date

Not Registered

Published for Opposition

August 23, 2022

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies for therapeutic use for treating viral infections, inflammatory diseases, cardiovascular diseases, auto-immune diseases, blood diseases, and cancers

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 24, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 24, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 22, 2025 EXRA
SOU EXTENSION 5 GRANTED
Jul 22, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 21, 2025 AITU
SOU TEAS EXTENSION RECEIVED
Apr 7, 2025 EEXT
SOU EXTENSION 5 FILED
Apr 6, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 30, 2024 EXRA
SOU EXTENSION 4 GRANTED
Sep 30, 2024 EX4G
SOU EXTENSION 4 FILED
Sep 30, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 30, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 15, 2024 EXRA
SOU EXTENSION 3 GRANTED
Mar 14, 2024 EX3G
SOU EXTENSION 3 FILED
Mar 14, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 5, 2023 EXRA
SOU EXTENSION 2 GRANTED
Oct 3, 2023 EX2G
SOU EXTENSION 2 FILED
Oct 3, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 3, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 31, 2023 EXRA
SOU EXTENSION 1 GRANTED
Mar 29, 2023 EX1G
SOU EXTENSION 1 FILED
Mar 29, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 29, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 18, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 23, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 23, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 3, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 20, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 20, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 20, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 20, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 20, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 18, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 18, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 21, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 21, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 21, 2022 CNRT
ASSIGNED TO EXAMINER
Jan 18, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 10, 2021 NWOS
NEW APPLICATION ENTERED
May 14, 2021 NWAP